Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 5

1.

A randomized controlled trial of intranasal ketamine in migraine with prolonged aura.

Afridi SK, Giffin NJ, Kaube H, Goadsby PJ.

Neurology. 2013 Feb 12;80(7):642-7. doi: 10.1212/WNL.0b013e3182824e66. Epub 2013 Jan 30.

PMID:
23365053
2.

The typical duration of migraine aura: a systematic review.

Viana M, Sprenger T, Andelova M, Goadsby PJ.

Cephalalgia. 2013 May;33(7):483-90. doi: 10.1177/0333102413479834. Epub 2013 Mar 8. Review.

PMID:
23475294
3.

Intranasal drug delivery in neuropsychiatry: focus on intranasal ketamine for refractory depression.

Andrade C.

J Clin Psychiatry. 2015 May;76(5):e628-31. doi: 10.4088/JCP.15f10026. Review.

4.

Use of Intranasal Ketamine for the Severely Agitated or Violent ED Patient.

Normandin PA, Khorey SJ, Donahue MA, Benotti SA, Manning BA.

J Emerg Nurs. 2016 Jan;42(1):61-3. doi: 10.1016/j.jen.2015.09.017. Epub 2015 Nov 5. Review. No abstract available.

PMID:
26547576
5.

[Ketamine as antidepressant: the current study situation].

Ritter PS, Bauer M, Pilhatsch M.

Nervenarzt. 2014 Nov;85(11):1432-5. doi: 10.1007/s00115-014-4132-5. Review. German.

PMID:
25324145

Supplemental Content

Support Center